Chardan Capital Reiterates a Hold Rating on Vascular Biogenics (VBLT)

By Jason Carr

In a report released today, Geulah Livshits from Chardan Capital reiterated a Hold rating on Vascular Biogenics (VBLTResearch Report), with a price target of $3. The company’s shares closed last Monday at $1.17.

According to, Livshits is a 4-star analyst with an average return of 10.8% and a 44.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vascular Biogenics with a $2.94 average price target.

See today’s analyst top recommended stocks >>

Based on Vascular Biogenics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.18 million. In comparison, last year the company had a GAAP net loss of $4.05 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.